Claims for Patent: 5,153,197

Summary for Patent: 5,153,197

Title:	Treatment of hypertension with angiotensin II blocking imidazoles
Abstract:	Substituted imidazoles such as ##STR1## are useful as angiotensin II blockers. These compounds have activity in treating hypertension and congestive heart failure.
Inventor(s):	David J. Carini, John J. V. Duncia
Assignee:	EIDP Inc
Application Number:	US07/436,165
Patent Claims:	1. A method of treating hypertension in a warm-blooded animal comprising administering to the animal, in an amount effective to lower the animal's blood pressure, an antihypertensive compound of the formula: ##STR493## wherein: R1 is ##STR494## R2 is H, Cl, Br, I, F, NO2, CN, alkyl of 1 to 4 carbon atoms, acyloxy of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, CO2 H, CO2 R9, NHSO2 CH3, NHSO2 CF3, CONHOR12, SO2 NH2, aryl, furyl or ##STR495## R3 is H, Cl, Br, I, F, alkyl of 1 to 4 carbon atoms, or alkoxy of 1 to 4 carbon atoms;R4 is CN, NO2, or CO2 R11 ; R5 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkenyl or alkynyl of 2 to 4 carbon atoms; R6 is alkyl of 2 to 10 carbon atoms, alkenyl or alkynyl of 3 to 10 carbon atoms or the same groups substituted with F or CO2 R14 ; cycloalkyl of 3 to 8 carbon atoms; cycloalkylalkyl of 4 to 10 carbon atoms; cycloalkylalkenyl or cycloalkylalkynyl of 5 to 10 carbon atoms; (CH2)s Z(CH2)m R5 optionally substituted with F or CO2 R14 ; benzyl or benzyl substituted on the phenyl ring with 1 or 2 halogens, alkoxy of 1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms or nitro; R7 is H, F, Cl, Br, I, NO2, Cv F2v+1, where v=1-6, C6 F5, ##STR496## straight or branched alkyl of 1 to 6 carbon atoms; phenyl or phenylalkyl, where alkyl is 1 to 3 carbon atoms; or substituted phenyl or substituted phenylalkyl, where alkyl is 1 to 3 carbon atoms, substituted with one or two substituents selected from alkyl of 1 to 4 carbon atoms, F, Cl, Br, OH, OCH3, CF3, and COOR, where R is H, alkyl of 1 to 4 carbon atoms, or phenyl; R8 is H, CN, alkyl of 1 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, or the same groups substituted with F; phenylalkenyl wherein the alkenyl portion is 2 to 6 carbon atoms; --(CH2)m -imidazol-1-yl; --(CH2)m -1,2,3-triazolyl optionally substituted with one or two groups selected from CO2 CH3 or alkyl of 1 to 4 carbon atoms; --(CH2)s --tetrazolyl; ##STR497## R9 is ##STR498## R10 is alkyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or (CH2)p C6 H5 ; R11 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R12 is H, methyl, or benzyl; R13 is ##STR499## R14 is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R15 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4 carbon atoms, or phenacyl; R16 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, (CH2)p C6 H5, OR17, or NR18 R19 ; R17 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R18 and R19 independently H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, α-methylbenzyl, or taken together with the nitrogen form a ring of the formula: ##STR500## Q is NR20, O or CH2 ; R20 is H, alkyl of 1 to 4 carbon atoms or phenyl; R21 is alkyl or 1 to 6 carbon atoms, --NR22 R23, or ##STR501## R22 and R23 independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as (CH2)u, where u is 3-6; R24 is H, CH3 or C6 H5 ; R25 is NR27 R28, OR28, NHCONH2, NHCSNH2, ##STR502## R26 is H, alkyl with from 1 to 6 carbon atoms, benzyl or allyl; R27 and R28 are independently H, alkyl with from 1 to 5 carbon atoms, or phenyl; R29 and R30 are independently alkyl of 1 to 4 carbon atoms, or taken together are --(CH2)q --; R31 is H, alkyl of 1 to 4 carbon atoms, --CH2 CH═CH2 or --CH2 C6 H4 R32 ; R32 is H, NO2, NH2, OH or OCH3 ; X is a carbon-carbon single bond, --CO--, --CH2 --, --O--, --S--, --NH--, ##STR503## --OCH2 --, --CH2 O, --SCH2 --, --CH2 S--, --NHC(R27)(R28)--, --NR23 SO2 --, --SO2 NR23 --, --C(R27)(R28)NH--, --CH═CH--, --CF═CF--, --CH═CF--, --CF═CH--, --CH2 CH2 --, --CF2 CF2 --, ##STR504## Y is O or S; Z is O, NR11, or S; m is 1 to 5; n is 1 to 10; p is 0 to 3; q is 2 to 3; r is 0 to 2; s is 0 to 5; t is 0 or 1; and pharmaceutically acceptable salts of these compounds;provided that: (1) the R1 group is not in the ortho position; (2) when R1 is ##STR505## X is a single bond, and R13 is ##STR506## then R13 must be in the ortho or meta position; or when R1 and X are as above and R13 is NHSO2 CF3 or NHSO2 CH3, R13 must be ortho; (3) when R1 is ##STR507## and X is other than a single bond, then R13 must be ortho, except when X= NR23 CO and R13 is NHSO2 CF3 or NHSO2 CH3, then R13 must be ortho or meta; (4) when R1 is 4-CO2 H or a salt thereof, R6 cannot be S-alkyl; (5) when R1 is 4-CO2 H or a salt thereof, the substituent on the 4-position of the imidazole cannot be CH2 OH, CH2 OCOCH3 or CH2 CO2 H; (6) when R1 is ##STR508## X is --OCH2 --, and R13 is 2-CO2 H, and R7 is H, then R6 is not C2 H5 S; (7) when R1 is ##STR509## and R6 is n-hexyl, then R7 and R8 are not both hydrogen; (8) when R1 is ##STR510## R6 is not methoxybenzyl; (9) the R6 group is not ##STR511## or CH2 OH; (10) when r=0, R1 is ##STR512## R13 is 2-NHSO2 CF3, and R6 is n-propyl, then R7 and R8 are not --CO2 CH3 ; (11) when r=0, R1 is ##STR513## R13 is 2-COOH, and R6 is n-propyl, then R7 and R8 are not --CO2 CH3 ; (12) when r=1, R1 is ##STR514## X is a single bond, R7 is Cl and R8 is --CHO, then R13 is not 3-(tetrazol-5-yl); (13) when r=1, R1 is ##STR515## X is a single bond, R7 is Cl and R8 is --CHO, then R13 is not 4-(tetrazol-5-yl); (14) when r=0, then R1 is not 4-NHSO2 CH3 or 4-NHSO2 CF3. 2. Method of claim 1 wherein the antihypertensive compound is a compound having the formula: ##STR516## wherein R1 is --CO2 H; --NHSO2 CF3 ; ##STR517## R6 is alkyl of 3 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, alkynyl of 3 to 10 carbon atoms; cycloalkyl of 3 to 8 carbon atoms; benzyl or benzyl substituted on the phenyl ring with 1 or 2 groups selected from alkoxy of 1 to 4 carbon atoms, halogen, alkyl of 1 to 4 carbon atoms, and nitro;R8 is phenylalkenyl wherein the aliphatic portion is 2 to 4 carbon atoms; --(CH2)m -imidazol-1-yl; --(CH2)m -1,2,3-triazolyl optionally substituted with one or two groups selected from CO2 CH3 or alkyl of 1 to 4 carbon atoms; --(CH2)m -tetrazolyl; ##STR518## R13 is --CO2 H, --CO2 R9, NHSO2 CF3, SO3 H or ##STR519## R16 is H, alkyl of 1 to 5 carbon atoms, OR17 or NR18 R19 ; X is a carbon-carbon single bond, --CO--, --CONR23 --, --CH2 CH2 --, ----NR23 CO----, --OCH2 --, --CH2 O, --O--, --SCH2 --, CH2 S--, --NHCH2 --, --CH2 NH-- or --CH═CH--;or a pharmaceutically suitable salt thereof. 3. Method of claim 2 wherein the antihypertensive compound is a compound wherein:R2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms; R6 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms; R7 is H, Cl, Br, I; Cv F2v+1, where v=1-3; or -COR16 ; R8 is ##STR520## R10 is CF3, alkyl of 1 to 6 carbon atoms, or phenyl; R11 is H or alkyl oF 1 to 4 carbon atoms; R13 is CO2 H, CO2 CH2 OCOC(CH3)3 ; NHSO2 CF3 ; or ##STR521## R14 is H, alkyl of 1 to 4 carbon atoms; R15 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms; R16 is H, alkyl of 1 to 5 carbon atoms; OR17 ; or ##STR522## m is 1 to 5; X is a single bond, --O--, --CO--, --NHCO-- or --OCH2--;or a pharmaceutically suitable salt thereof. 4. Method of claim 3 wherein the antihypertensive compound is a compound wherein R1 is ##STR523## and X is a single bond; or a pharmaceutically suitable salt thereof. 5. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 6. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)-imidazole, or a pharmaceutically acceptable salt thereof. 7. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(methoxycarbonyl)-aminomethyl]imidazole, or a pharmaceutically acceptable salt thereof. 8. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(propoxycarbonyl)-aminomethyl]imidazole, or a pharmaceutically acceptable salt thereof. 9. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 10. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 11. Method of claim 4 wherein the antihypertensive compound is 2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 12. Method of claim 4 wherein the antihypertensive compound is 2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 13. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 14. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 15. Method of claim 4 wherein the antihypertensive compound is 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 16. Method of claim 4 wherein the antihypertensive compound is 2-(1E-butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 17. Method of claim 4 wherein the antihypertensive compound is 2-(1E-butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 18. Method of claim 4 wherein the antihypertensive compound is 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 19. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 20. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 21. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 22. Method of claim 4 wherein the antihypertensive compound is 2-butyl-4-trifluoromethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 23. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-trifluoromethyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 24. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 25. Method of claim 4 wherein the antihypertensive compound is 2-Propyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-4,5-dicarboxylic acid, or a pharmaceutically acceptable salt thereof. 26. Method of claim 4 wherein the antihypertensive compound is 2-Propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 27. Method of claim 4 wherein the antihypertensive compound is 2-Propyl-4-pentafluoroethyl-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 28. A pharmaceutical composition comprising a pharmaceutically suitable carrier, a diuretic and an antihypertensive compound of the formula ##STR524## wherein: R1 is ##STR525## R2 is H, Cl, Br, I, F, NO2, CN, alkyl of 1 to 4 carbon atoms, acyloxy of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, CO2 H, CO2 R9, NHSO2 CH3, NHSO2 CF3, CONHOR12, SO2 NH2, aryl, furyl or ##STR526## R3 is H, Cl, Br, I, F, alkyl of 1 to 4 carbon atoms, or alkoxy of 1 to 4 carbon atoms;R4 is CN, NO2, or CO2 R11 ; R5 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkenyl or alkynyl of 2 to 4 carbon atoms; R6 is alkyl of 2 to 10 carbon atoms, alkenyl or alkynyl of 3 to 10 carbon atoms or the same groups substituted with F or CO2 R14 ; cycloalkyl of 3 to 8 carbon atoms; cycloalkylalkyl of 4 to 10 carbon atoms; cycloalkylalkenyl or cycloalkylalkynyl of 5 to 10 carbon atoms; (CH2)s Z(CH2)m R5 optionally substituted with F or CO2 R14 ; benzyl or benzyl substituted on the phenyl ring with 1 or 2 halogens, alkoxy of 1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms or nitro; R7 is H, F, Cl, Br, I, NO2, Cv F2v+1, where v=1-6, C6 F5, CN, ##STR527## straight or branched alkyl of 1 to 6 carbon atoms; phenyl or phenylalkyl, where alkyl is 1 to 3 carbon atoms; or substituted phenyl or substituted phenylalkyl, where alkyl is 1 to 3 carbon atoms, substituted with one or two substituents selected from alkyl of 1 to 4 carbon atoms, F, Cl, Br, OH, OCH3, CF3, and COOR, where R is H, alkyl of 1 to 4 carbon atoms, or phenyl; R8 is H, CN, alkyl of 1 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, or the same groups substituted with F; phenylalkenyl wherein the alkenyl portion is 2 to 6 carbon atoms; --(CH2)s -tetrazolyl; ##STR528## R9 is ##STR529## R10 is alkyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or (CH2)p C6 H5 ; R11 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R12 is H, methyl, or benzyl; R13 is ##STR530## R14 is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R15 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4 carbon atoms, or phenacyl; R16 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, (CH2)p C6 H5, OR17, or NR18 R19 ; R17 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R18 and R19 independently H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, α-methylbenzyl, R20 is H, alkyl of 1 to 4 carbon atoms or phenyl; R21 is alkyl or 1 to 6 carbon atoms, --NR22 R23, or ##STR531## R22 and R23 independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as (CH2)u, where u is 3-6; R24 is H, CH3 or C6 H5 ; R25 is NR27 R28, OR28, NHCONH2, NHCSNH2, ##STR532## R26 is H, alkyl with from 1 to 6 carbon atoms, benzyl or allyl; R27 and R28 are independently H, alkyl with from 1 to 5 carbon atoms, or phenyl; R29 and R30 are independently alkyl of 1 to 4 carbon atoms, or taken together are --(CH2)q --; R31 is H, alkyl of 1 to 4 carbon atoms, --CH2 CH═CH2 or --CH2 C6 H4 R32 ; R32 is H, NO2, NH2, OH or OCH3 ; X is a carbon-carbon single bond, --CO--, --CH2 --, --O--, --S--, --NH--, ##STR533## --OCH2 --, --CH2 O, --SCH2 --, --CH2 S--, --NHC(R27)(R28)--, --NR23 SO2 --, --SO2 NR23 --, --C(R27)(R28)NH--, --CH═CH--, --CF═CF--, --CH═CF--, --CF═CH--, --CH2 CH2 --, --CF2 CF2 --, ##STR534## Y is O or S; Z is O, NR11, or S; m is 1 to 5; n is 1 to 10; p is 0 to 3; q is 2 to 3; r is 0 to 2; s is 0 to 5; t is 0 or 1;and pharmaceutically acceptable salts of these compounds; provided that: (1) the R1 group is not in the ortho position; (2) when R1 is ##STR535## X is a single bond, and R13 is CO2 H or ##STR536## then R13 must be in the ortho or meta position; or when R1 and X are as above and R13 is NHSO2 CF3 or NHSO2 CH3, R13 must be ortho; (3) when R1 is ##STR537## and X is other than a single bond, then R13 must be ortho, except when X=NR23 CO and R13 is NHSO2 CF3 or NHSO2 CH3, then R13 must be ortho or meta; (4) when R1 is 4-CO2 H or a salt thereof, R6 cannot be S-alkyl; (5) when R1 is 4-CO2 H or a salt thereof, the substituent on the 4-position of the imidazole cannot be CH2 OH, CH2 OCOCH3 or CH2 CO2 H; (6) when R1 is ##STR538## X is --OCH2 --, and R13 is 2-CO2 H, and R7 is H, then R6 is not C2 H5 S; (7) when R1 is ##STR539## and R6 is n-hexyl, then R7 and R8 are not both hydrogen; (8) when R1 is ##STR540## R6 is not methoxybenzyl; (9) the R6 group is not ##STR541## (10) when r=0, R1 is ##STR542## R13 is 2-NHSO2 CF3, and R6 is n-propyl, then R7 and R8 are not --CO2 CH3 ; (11) when r=0, R1 is ##STR543## R13 is 2-COOH, and R6 is n-propyl, then R7 and R8 are not --CO2 CH3 ; (12) when r=1, R1 is ##STR544## X is a single bond, R7 is Cl and R8 is --CHO, then R13 is not 3-(tetrazol-5-yl); (13) when r=1, R1 is ##STR545## X is a single bond, R7 is Cl and R8 is --CHO, then R13 is not 4-(tetrazol-5-yl); (14) when r=0, then R1 is not 4-NHSO2 CH3 or 4-NHSO2 CF3 ; and (15) at least one of R1, R2, R8 or R13 be a tetrazole group or a group containing a tetrazole substituent. 29. Pharmaecutical composition of claim 28 wherein the antihypertensive compound is a compound having the formula: ##STR546## wherein R1 is ##STR547## R6 is alkyl of 3 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, alkynyl of 3 to 10 carbon atoms; cycloalkyl of 3 to 8 carbon atoms; benzyl or benzyl substituted on the phenyl ring with 1 or 2 groups selected from alkoxy of 1 to 4 carbon atoms, halogen, alkyl of 1 to 4 carbon atoms, and nitro;R8 is phenylalkenyl wherein the aliphatic portion is 2 to 4 carbon atoms; --(CH2)m -tetrazolyl; ##STR548## R13 is --CO2 H, --CO2 R9, NHSO2 CF3, SO3 H or ##STR549## R16 is H, alkyl of 1 to 5 carbon atoms, OR17 or NR18 R19 ;X is a carbon-carbon single bond, --CO--, --CONR23 --, --CH2 CH2 --, ----NR23 CO----, --OCH2 --, --CH2 O, --O--, --SCH2 --, --CH2 S--, --NHCH2 --, --CH2 NH-- or --CH═CH--; or a pharmaceutically suitable salt thereof; provided that at least one of R1, R2, R8 or R13 be a tetrazole group or a group containing a tetrazole substituent. 30. Pharmaceutical composition of claim 29 wherein the antihypertensive compound is a compound wherein:R2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms; R6 is alkyl, alkeny or alkynyl of 3 to 7 carbon atoms; R7 is H, Cl, Br, I; Cv F2v+1, where v=1-3; or --COR16 ; R8 is ##STR550## R10 is CF3, alkyl of 1 to 6 carbon atoms, or phenyl; R11 is H or alkyl oF 1 to 4 carbon atoms; R13 is CO2 H, CO2 CH2 OCOC(CH3)3 ; NHSO2 CF3 ; or ##STR551## R14 is H, alkyl of 1 to 4 carbon atoms; R15 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms; R16 is H, alkyl of 1 to 5 carbon atoms; OR17 ; m is 1 to 5; X is a single bond, --O--, --CO--, --NHCO-- or --OCH2--; or a pharmaceutically suitable salt thereof; provided that at least one of R1 or R13 be a tetrazole group or a group containing a tetrazole substituent. PG,394 31. Pharmaceutical composition of claim 30 wherein the antihypertensive compound is a compound wherein R1 is ##STR552## and X is a single bond; or a pharmaceutically suitable salt thereof. 32. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 33. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 34. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 35. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 36. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-(1E-butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 37. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-(1E-butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 38. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 39. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 40. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-tri-fluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 41. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-tri-fluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 42. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-butyl-4-tri-fluoromethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 43. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 44. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-Propyl-1-[(2'-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-4,5-dicarboxylic acid, or a pharmaceutically acceptable salt thereof. 45. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-Propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 46. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-Propyl-4-pentafluoroethyl-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 1. A method of treating hypertension in a warm-blooded animal comprising administering to the animal, in an amount effective to lower the animal's blood pressure, an antihypertensive compound of the formula: ##STR493## wherein: R.sup.1 is ##STR494## R.sup.2 is H, Cl, Br, I, F, NO.sub.2, CN, alkyl of 1 to 4 carbon atoms, acyloxy of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, CO.sub.2 H, CO.sub.2 R.sup.9, NHSO.sub.2 CH.sub.3, NHSO.sub.2 CF.sub.3, CONHOR.sup.12, SO.sub.2 NH.sub.2, aryl, furyl or ##STR495## R.sup.3 is H, Cl, Br, I, F, alkyl of 1 to 4 carbon atoms, or alkoxy of 1 to 4 carbon atoms; R.sup.4 is CN, NO.sub.2, or CO.sub.2 R.sup.11 ; R.sup.5 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkenyl or alkynyl of 2 to 4 carbon atoms; R.sup.6 is alkyl of 2 to 10 carbon atoms, alkenyl or alkynyl of 3 to 10 carbon atoms or the same groups substituted with F or CO.sub.2 R.sup.14 ; cycloalkyl of 3 to 8 carbon atoms; cycloalkylalkyl of 4 to 10 carbon atoms; cycloalkylalkenyl or cycloalkylalkynyl of 5 to 10 carbon atoms; (CH.sub.2).sub.s Z(CH.sub.2).sub.m R.sup.5 optionally substituted with F or CO.sub.2 R.sup.14 ; benzyl or benzyl substituted on the phenyl ring with 1 or 2 halogens, alkoxy of 1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms or nitro; R.sup.7 is H, F, Cl, Br, I, NO.sub.2, C.sub.v F.sub.2v+1, where v=1-6, C.sub.6 F.sub.5, ##STR496## straight or branched alkyl of 1 to 6 carbon atoms; phenyl or phenylalkyl, where alkyl is 1 to 3 carbon atoms; or substituted phenyl or substituted phenylalkyl, where alkyl is 1 to 3 carbon atoms, substituted with one or two substituents selected from alkyl of 1 to 4 carbon atoms, F, Cl, Br, OH, OCH.sub.3, CF.sub.3, and COOR, where R is H, alkyl of 1 to 4 carbon atoms, or phenyl; R.sup.8 is H, CN, alkyl of 1 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, or the same groups substituted with F; phenylalkenyl wherein the alkenyl portion is 2 to 6 carbon atoms; --(CH.sub.2).sub.m -imidazol-1-yl; --(CH.sub.2).sub.m -1,2,3-triazolyl optionally substituted with one or two groups selected from CO.sub.2 CH.sub.3 or alkyl of 1 to 4 carbon atoms; --(CH.sub.2).sub.s --tetrazolyl; ##STR497## R.sup.9 is ##STR498## R.sup.10 is alkyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or (CH.sub.2).sub.p C.sub.6 H.sub.5 ; R.sup.11 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R.sup.12 is H, methyl, or benzyl; R.sup.13 is ##STR499## R.sup.14 is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R.sup.15 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4 carbon atoms, or phenacyl; R.sup.16 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, (CH.sub.2).sub.p C.sub.6 H.sub.5, OR.sup.17, or NR.sup.18 R.sup.19 ; R.sup.17 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R.sup.18 and R.sup.19 independently H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, .alpha.-methylbenzyl, or taken together with the nitrogen form a ring of the formula: ##STR500## Q is NR.sup.20, O or CH.sub.2 ; R.sup.20 is H, alkyl of 1 to 4 carbon atoms or phenyl; R.sup.21 is alkyl or 1 to 6 carbon atoms, --NR.sup.22 R.sup.23, or ##STR501## R.sup.22 and R.sup.23 independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as (CH.sub.2).sub.u, where u is 3-6; R.sup.24 is H, CH.sub.3 or C.sub.6 H.sub.5 ; R.sup.25 is NR.sup.27 R.sup.28, OR.sup.28, NHCONH.sub.2, NHCSNH.sub.2, ##STR502## R.sup.26 is H, alkyl with from 1 to 6 carbon atoms, benzyl or allyl; R.sup.27 and R.sup.28 are independently H, alkyl with from 1 to 5 carbon atoms, or phenyl; R.sup.29 and R.sup.30 are independently alkyl of 1 to 4 carbon atoms, or taken together are --(CH.sub.2).sub.q --; R.sup.31 is H, alkyl of 1 to 4 carbon atoms, --CH.sub.2 CH.dbd.CH.sub.2 or --CH.sub.2 C.sub.6 H.sub.4 R.sup.32 ; R.sup.32 is H, NO.sub.2, NH.sub.2, OH or OCH.sub.3 ; X is a carbon-carbon single bond, --CO--, --CH.sub.2 --, --O--, --S--, --NH--, ##STR503## --OCH.sub.2 --, --CH.sub.2 O, --SCH.sub.2 --, --CH.sub.2 S--, --NHC(R.sup.27)(R.sup.28)--, --NR.sup.23 SO.sub.2 --, --SO.sub.2 NR.sup.23 --, --C(R.sup.27)(R.sup.28)NH--, --CH.dbd.CH--, --CF.dbd.CF--, --CH.dbd.CF--, --CF.dbd.CH--, --CH.sub.2 CH.sub.2 --, --CF.sub.2 CF.sub.2 --, ##STR504## Y is O or S; Z is O, NR.sup.11, or S; m is 1 to 5; n is 1 to 10; p is 0 to 3; q is 2 to 3; r is 0 to 2; s is 0 to 5; t is 0 or 1; and pharmaceutically acceptable salts of these compounds; provided that: (1) the R.sup.1 group is not in the ortho position; (2) when R.sup.1 is ##STR505## X is a single bond, and R.sup.13 is ##STR506## then R.sup.13 must be in the ortho or meta position; or when R.sup.1 and X are as above and R.sup.13 is NHSO.sub.2 CF.sub.3 or NHSO.sub.2 CH.sub.3, R.sup.13 must be ortho; (3) when R.sup.1 is ##STR507## and X is other than a single bond, then R.sup.13 must be ortho, except when X= NR.sup.23 CO and R.sup.13 is NHSO.sub.2 CF.sub.3 or NHSO.sub.2 CH.sub.3, then R.sup.13 must be ortho or meta; (4) when R.sup.1 is 4-CO.sub.2 H or a salt thereof, R.sup.6 cannot be S-alkyl; (5) when R.sup.1 is 4-CO.sub.2 H or a salt thereof, the substituent on the 4-position of the imidazole cannot be CH.sub.2 OH, CH.sub.2 OCOCH.sub.3 or CH.sub.2 CO.sub.2 H; (6) when R.sup.1 is ##STR508## X is --OCH.sub.2 --, and R.sup.13 is 2-CO.sub.2 H, and R.sup.7 is H, then R.sup.6 is not C.sub.2 H.sub.5 S; (7) when R.sup.1 is ##STR509## and R.sup.6 is n-hexyl, then R.sup.7 and R.sup.8 are not both hydrogen; (8) when R.sup.1 is ##STR510## R.sup.6 is not methoxybenzyl; (9) the R.sup.6 group is not ##STR511## or CH.sub.2 OH; (10) when r=0, R.sup.1 is ##STR512## R.sup.13 is 2-NHSO.sub.2 CF.sub.3, and R.sup.6 is n-propyl, then R.sup.7 and R.sup.8 are not --CO.sub.2 CH.sub.3 ; (11) when r=0, R.sup.1 is ##STR513## R.sup.13 is 2-COOH, and R.sup.6 is n-propyl, then R.sup.7 and R.sup.8 are not --CO.sub.2 CH.sub.3 ; (12) when r=1, R.sup.1 is ##STR514## X is a single bond, R.sup.7 is Cl and R.sup.8 is --CHO, then R.sup.13 is not 3-(tetrazol-5-yl); (13) when r=1, R.sup.1 is ##STR515## X is a single bond, R.sup.7 is Cl and R.sup.8 is --CHO, then R.sup.13 is not 4-(tetrazol-5-yl); (14) when r=0, then R.sup.1 is not 4-NHSO.sub.2 CH.sub.3 or 4-NHSO.sub.2 CF.sub.3. 2. Method of claim 1 wherein the antihypertensive compound is a compound having the formula: ##STR516## wherein R.sup.1 is --CO.sub.2 H; --NHSO.sub.2 CF.sub.3 ; ##STR517## R.sup.6 is alkyl of 3 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, alkynyl of 3 to 10 carbon atoms; cycloalkyl of 3 to 8 carbon atoms; benzyl or benzyl substituted on the phenyl ring with 1 or 2 groups selected from alkoxy of 1 to 4 carbon atoms, halogen, alkyl of 1 to 4 carbon atoms, and nitro; R.sup.8 is phenylalkenyl wherein the aliphatic portion is 2 to 4 carbon atoms; --(CH.sub.2).sub.m -imidazol-1-yl; --(CH.sub.2).sub.m -1,2,3-triazolyl optionally substituted with one or two groups selected from CO.sub.2 CH.sub.3 or alkyl of 1 to 4 carbon atoms; --(CH.sub.2).sub.m -tetrazolyl; ##STR518## R.sup.13 is --CO.sub.2 H, --CO.sub.2 R.sup.9, NHSO.sub.2 CF.sub.3, SO.sub.3 H or ##STR519## R.sup.16 is H, alkyl of 1 to 5 carbon atoms, OR.sup.17 or NR.sup.18 R.sup.19 ; X is a carbon-carbon single bond, --CO--, --CONR.sup.23 --, --CH.sub.2 CH.sub.2 --, ----NR.sup.23 CO----, --OCH.sub.2 --, --CH.sub.2 O, --O--, --SCH.sub.2 --, CH.sub.2 S--, --NHCH.sub.2 --, --CH.sub.2 NH-- or --CH.dbd.CH--; or a pharmaceutically suitable salt thereof. 3. Method of claim 2 wherein the antihypertensive compound is a compound wherein: R.sup.2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms; R.sup.6 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms; R.sup.7 is H, Cl, Br, I; C.sub.v F.sub.2v+1, where v=1-3; or -COR.sup.16 ; R.sup.8 is ##STR520## R.sup.10 is CF.sub.3, alkyl of 1 to 6 carbon atoms, or phenyl; R.sup.11 is H or alkyl oF 1 to 4 carbon atoms; R.sup.13 is CO.sub.2 H, CO.sub.2 CH.sub.2 OCOC(CH.sub.3).sub.3 ; NHSO.sub.2 CF.sub.3 ; or ##STR521## R.sup.14 is H, alkyl of 1 to 4 carbon atoms; R.sup.15 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms; R.sup.16 is H, alkyl of 1 to 5 carbon atoms; OR.sup.17 ; or ##STR522## m is 1 to 5; X is a single bond, --O--, --CO--, --NHCO-- or --OCH2--; or a pharmaceutically suitable salt thereof. 4. Method of claim 3 wherein the antihypertensive compound is a compound wherein R.sup.1 is ##STR523## and X is a single bond; or a pharmaceutically suitable salt thereof. 5. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxy methyl)imidazole, or a pharmaceutically acceptable salt thereof. 6. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)-imi dazole, or a pharmaceutically acceptable salt thereof. 7. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(methoxycarbonyl)- aminomethyl]imidazole, or a pharmaceutically acceptable salt thereof. 8. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(propoxycarbonyl)- aminomethyl]imidazole, or a pharmaceutically acceptable salt thereof. 9. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxalde hyde, or a pharmaceutically acceptable salt thereof. 10. Method of claim 4 wherein the antihypertensive compound is 2-Butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 11. Method of claim 4 wherein the antihypertensive compound is 2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymeth yl)imidazole, or a pharmaceutically acceptable salt thereof. 12. Method of claim 4 wherein the antihypertensive compound is 2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-car boxaldehyde, or a pharmaceutically acceptable salt thereof. 13. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydrox ymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 14. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole- 5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 15. Method of claim 4 wherein the antihypertensive compound is 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5 -carboxaldehyde, or a pharmaceutically acceptable salt thereof. 16. Method of claim 4 wherein the antihypertensive compound is 2-(1E-butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-h ydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 17. Method of claim 4 wherein the antihypertensive compound is 2-(1E-butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imi dazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 18. Method of claim 4 wherein the antihypertensive compound is 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole- 5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 19. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole -5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 20. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl] imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 21. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl- 5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 22. Method of claim 4 wherein the antihypertensive compound is 2-butyl-4-trifluoromethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]im idazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 23. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-trifluoromethyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-imidazole-5 -carboxaldehyde, or a pharmaceutically acceptable salt thereof. 24. Method of claim 4 wherein the antihypertensive compound is 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl] -5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 25. Method of claim 4 wherein the antihypertensive compound is 2-Propyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-4,5-dicar boxylic acid, or a pharmaceutically acceptable salt thereof. 26. Method of claim 4 wherein the antihypertensive compound is 2-Propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl] imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 27. Method of claim 4 wherein the antihypertensive compound is 2-Propyl-4-pentafluoroethyl-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]im idazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 28. A pharmaceutical composition comprising a pharmaceutically suitable carrier, a diuretic and an antihypertensive compound of the formula ##STR524## wherein: R.sup.1 is ##STR525## R.sup.2 is H, Cl, Br, I, F, NO.sub.2, CN, alkyl of 1 to 4 carbon atoms, acyloxy of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, CO.sub.2 H, CO.sub.2 R.sup.9, NHSO.sub.2 CH.sub.3, NHSO.sub.2 CF.sub.3, CONHOR.sup.12, SO.sub.2 NH.sub.2, aryl, furyl or ##STR526## R.sup.3 is H, Cl, Br, I, F, alkyl of 1 to 4 carbon atoms, or alkoxy of 1 to 4 carbon atoms; R.sup.4 is CN, NO.sub.2, or CO.sub.2 R.sup.11 ; R.sup.5 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkenyl or alkynyl of 2 to 4 carbon atoms; R.sup.6 is alkyl of 2 to 10 carbon atoms, alkenyl or alkynyl of 3 to 10 carbon atoms or the same groups substituted with F or CO.sub.2 R.sup.14 ; cycloalkyl of 3 to 8 carbon atoms; cycloalkylalkyl of 4 to 10 carbon atoms; cycloalkylalkenyl or cycloalkylalkynyl of 5 to 10 carbon atoms; (CH.sub.2).sub.s Z(CH.sub.2).sub.m R.sup.5 optionally substituted with F or CO.sub.2 R.sup.14 ; benzyl or benzyl substituted on the phenyl ring with 1 or 2 halogens, alkoxy of 1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms or nitro; R.sup.7 is H, F, Cl, Br, I, NO.sub.2, C.sub.v F.sub.2v+1, where v=1-6, C.sub.6 F.sub.5, CN, ##STR527## straight or branched alkyl of 1 to 6 carbon atoms; phenyl or phenylalkyl, where alkyl is 1 to 3 carbon atoms; or substituted phenyl or substituted phenylalkyl, where alkyl is 1 to 3 carbon atoms, substituted with one or two substituents selected from alkyl of 1 to 4 carbon atoms, F, Cl, Br, OH, OCH.sub.3, CF.sub.3, and COOR, where R is H, alkyl of 1 to 4 carbon atoms, or phenyl; R.sup.8 is H, CN, alkyl of 1 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, or the same groups substituted with F; phenylalkenyl wherein the alkenyl portion is 2 to 6 carbon atoms; --(CH.sub.2).sub.s -tetrazolyl; ##STR528## R.sup.9 is ##STR529## R.sup.10 is alkyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or (CH.sub.2).sub.p C.sub.6 H.sub.5 ; R.sup.11 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R.sup.12 is H, methyl, or benzyl; R.sup.13 is ##STR530## R.sup.14 is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R.sup.15 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4 carbon atoms, or phenacyl; R.sup.16 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, (CH.sub.2).sub.p C.sub.6 H.sub.5, OR.sup.17, or NR.sup.18 R.sup.19 ; R.sup.17 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; R.sup.18 and R.sup.19 independently H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, .alpha.-methylbenzyl, R.sup.20 is H, alkyl of 1 to 4 carbon atoms or phenyl; R.sup.21 is alkyl or 1 to 6 carbon atoms, --NR.sup.22 R.sup.23, or ##STR531## R.sup.22 and R.sup.23 independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as (CH.sub.2).sub.u, where u is 3-6; R.sup.24 is H, CH.sub.3 or C.sub.6 H.sub.5 ; R.sup.25 is NR.sup.27 R.sup.28, OR.sup.28, NHCONH.sub.2, NHCSNH.sub.2, ##STR532## R.sup.26 is H, alkyl with from 1 to 6 carbon atoms, benzyl or allyl; R.sup.27 and R.sup.28 are independently H, alkyl with from 1 to 5 carbon atoms, or phenyl; R.sup.29 and R.sup.30 are independently alkyl of 1 to 4 carbon atoms, or taken together are --(CH.sub.2).sub.q --; R.sup.31 is H, alkyl of 1 to 4 carbon atoms, --CH.sub.2 CH.dbd.CH.sub.2 or --CH.sub.2 C.sub.6 H.sub.4 R.sup.32 ; R.sup.32 is H, NO.sub.2, NH.sub.2, OH or OCH.sub.3 ; X is a carbon-carbon single bond, --CO--, --CH.sub.2 --, --O--, --S--, --NH--, ##STR533## --OCH.sub.2 --, --CH.sub.2 O, --SCH.sub.2 --, --CH.sub.2 S--, --NHC(R.sup.27)(R.sup.28)--, --NR.sup.23 SO.sub.2 --, --SO.sub.2 NR.sup.23 --, --C(R.sup.27)(R.sup.28)NH--, --CH.dbd.CH--, --CF.dbd.CF--, --CH.dbd.CF--, --CF.dbd.CH--, --CH.sub.2 CH.sub.2 --, --CF.sub.2 CF.sub.2 --, ##STR534## Y is O or S; Z is O, NR.sup.11, or S; m is 1 to 5; n is 1 to 10; p is 0 to 3; q is 2 to 3; r is 0 to 2; s is 0 to 5; t is 0 or 1; and pharmaceutically acceptable salts of these compounds; provided that: (1) the R.sup.1 group is not in the ortho position; (2) when R.sup.1 is ##STR535## X is a single bond, and R.sup.13 is CO.sub.2 H or ##STR536## then R.sup.13 must be in the ortho or meta position; or when R.sup.1 and X are as above and R.sup.13 is NHSO.sub.2 CF.sub.3 or NHSO.sub.2 CH.sub.3, R.sup.13 must be ortho; (3) when R.sup.1 is ##STR537## and X is other than a single bond, then R.sup.13 must be ortho, except when X=NR.sup.23 CO and R.sup.13 is NHSO.sub.2 CF.sub.3 or NHSO.sub.2 CH.sub.3, then R.sup.13 must be ortho or meta; (4) when R.sup.1 is 4-CO.sub.2 H or a salt thereof, R.sup.6 cannot be S-alkyl; (5) when R.sup.1 is 4-CO.sub.2 H or a salt thereof, the substituent on the 4-position of the imidazole cannot be CH.sub.2 OH, CH.sub.2 OCOCH.sub.3 or CH.sub.2 CO.sub.2 H; (6) when R.sup.1 is ##STR538## X is --OCH.sub.2 --, and R.sup.13 is 2-CO.sub.2 H, and R.sup.7 is H, then R.sup.6 is not C.sub.2 H.sub.5 S; (7) when R.sup.1 is ##STR539## and R.sup.6 is n-hexyl, then R.sup.7 and R.sup.8 are not both hydrogen; (8) when R.sup.1 is ##STR540## R.sup.6 is not methoxybenzyl; (9) the R.sup.6 group is not ##STR541## (10) when r=0, R.sup.1 is ##STR542## R.sup.13 is 2-NHSO.sub.2 CF.sub.3, and R.sup.6 is n-propyl, then R.sup.7 and R.sup.8 are not --CO.sub.2 CH.sub.3 ; (11) when r=0, R.sup.1 is ##STR543## R.sup.13 is 2-COOH, and R.sup.6 is n-propyl, then R.sup.7 and R.sup.8 are not --CO.sub.2 CH.sub.3 ; (12) when r=1, R.sup.1 is ##STR544## X is a single bond, R.sup.7 is Cl and R.sup.8 is --CHO, then R.sup.13 is not 3-(tetrazol-5-yl); (13) when r=1, R.sup.1 is ##STR545## X is a single bond, R.sup.7 is Cl and R.sup.8 is --CHO, then R.sup.13 is not 4-(tetrazol-5-yl); (14) when r=0, then R.sup.1 is not 4-NHSO.sub.2 CH.sub.3 or 4-NHSO.sub.2 CF.sub.3 ; and (15) at least one of R.sup.1, R.sup.2, R.sup.8 or R.sup.13 be a tetrazole group or a group containing a tetrazole substituent. 29. Pharmaecutical composition of claim 28 wherein the antihypertensive compound is a compound having the formula: ##STR546## wherein R.sup.1 is ##STR547## R.sup.6 is alkyl of 3 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, alkynyl of 3 to 10 carbon atoms; cycloalkyl of 3 to 8 carbon atoms; benzyl or benzyl substituted on the phenyl ring with 1 or 2 groups selected from alkoxy of 1 to 4 carbon atoms, halogen, alkyl of 1 to 4 carbon atoms, and nitro; R.sup.8 is phenylalkenyl wherein the aliphatic portion is 2 to 4 carbon atoms; --(CH.sub.2).sub.m -tetrazolyl; ##STR548## R.sup.13 is --CO.sub.2 H, --CO.sub.2 R.sup.9, NHSO.sub.2 CF.sub.3, SO.sub.3 H or ##STR549## R.sup.16 is H, alkyl of 1 to 5 carbon atoms, OR.sup.17 or NR.sup.18 R.sup.19 ; X is a carbon-carbon single bond, --CO--, --CONR.sup.23 --, --CH.sub.2 CH.sub.2 --, ----NR.sup.23 CO----, --OCH.sub.2 --, --CH.sub.2 O, --O--, --SCH.sub.2 --, --CH.sub.2 S--, --NHCH.sub.2 --, --CH.sub.2 NH-- or --CH.dbd.CH--; or a pharmaceutically suitable salt thereof; provided that at least one of R.sup.1, R.sup.2, R.sup.8 or R.sup.13 be a tetrazole group or a group containing a tetrazole substituent. 30. Pharmaceutical composition of claim 29 wherein the antihypertensive compound is a compound wherein: R.sup.2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms; R.sup.6 is alkyl, alkeny or alkynyl of 3 to 7 carbon atoms; R.sup.7 is H, Cl, Br, I; C.sub.v F.sub.2v+1, where v=1-3; or --COR.sup.16 ; R.sup.8 is ##STR550## R.sup.10 is CF.sub.3, alkyl of 1 to 6 carbon atoms, or phenyl; R.sup.11 is H or alkyl oF 1 to 4 carbon atoms; R.sup.13 is CO.sub.2 H, CO.sub.2 CH.sub.2 OCOC(CH.sub.3).sub.3 ; NHSO.sub.2 CF.sub.3 ; or ##STR551## R.sup.14 is H, alkyl of 1 to 4 carbon atoms; R.sup.15 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms; R.sup.16 is H, alkyl of 1 to 5 carbon atoms; OR.sup.17 ; m is 1 to 5; X is a single bond, --O--, --CO--, --NHCO-- or --OCH2--; or a pharmaceutically suitable salt thereof; provided that at least one of R.sup.1 or R.sup.13 be a tetrazole group or a group containing a tetrazole substituent. PG,394 31. Pharmaceutical composition of claim 30 wherein the antihypertensive compound is a compound wherein R.sup.1 is ##STR552## and X is a single bond; or a pharmaceutically suitable salt thereof. 32. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxy methyl)imidazole, or a pharmaceutically acceptable salt thereof. 33. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydrox ymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 34. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole- 5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 35. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5 -carboxaldehyde, or a pharmaceutically acceptable salt thereof. 36. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-(1E-butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-h ydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 37. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-(1E-butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imi dazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof. 38. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole- 5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 39. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole -5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 40. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-tri-fluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl ]imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 41. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-tri-fluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl ]-5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 42. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-butyl-4-tri-fluoromethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]i midazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 43. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl] -5-(hydroxymethyl)imidazole, or a pharmaceutically acceptable salt thereof. 44. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-Propyl-1-[(2'-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-4,5-dica rboxylic acid, or a pharmaceutically acceptable salt thereof. 45. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-Propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl] imidazole-5-carboxylic acid, or a pharmaceutically acceptable salt thereof. 46. Pharmaceutical composition of claim 31 wherein the antihypertensive compound is 2-Propyl-4-pentafluoroethyl-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]im idazole-5-carboxaldehyde, or a pharmaceutically acceptable salt thereof.